Bayesian Capital Management, LP Recursion Pharmaceuticals, Inc. Transaction History
Bayesian Capital Management, LP
- $854 Million
- Q2 2024
A detailed history of Bayesian Capital Management, LP transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Bayesian Capital Management, LP holds 42,400 shares of RXRX stock, worth $295,952. This represents 0.04% of its overall portfolio holdings.
Number of Shares
42,400Holding current value
$295,952% of portfolio
0.04%Shares
6 transactions
Others Institutions Holding RXRX
# of Institutions
285Shares Held
236MCall Options Held
972KPut Options Held
2.4M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl28.1MShares$196 Million1.92% of portfolio
-
Baillie Gifford & CO26.6MShares$186 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA21.6MShares$150 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$121 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$107 Million1.74% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.26B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...